Business
Endonovo Announces Advancement of International “Go to Market” Initiative
Endonovo Announces Advancement of International “Go to Market” Initiative.
About this update from Endonovo Therapeutics, Inc.
[{"type":"text","content":"\n Los Angeles, CA, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced an aggressive initiative to introduce and develop the sales and benefits of SofPulse® medical devices into multiple international markets as part of its global “Go to Market” strategy. President and Chief Commercial Officer of the Medical Division of Endonovo, Ira Weisberg, will be heading the efforts to expand the benefits of SofPulse® into international markets. With the announcement, Weisberg reported: “We are presently negotiating with a major distribution partner to bring SofPulse® into South and Central America. Additionally, we are concurrently engaged in licensing and distribution discussions with recognized distribution partners in Australia, Europe and various Southeast Asian markets.” SofPulse® is completing the final stages of receiving regulatory clearance in Taiwan through Endonovo’s distribution partner Evermed Medical Enterprise, Ltd. Final Taiwan FDA approval is expected to be completed in the first half of 2023. “Go to Market” Global Strategy “Our international ‘Go to Market’ strategy is to introduce the benefits of SofPulse® into global markets to provide an alternative approach for the management of post-operative pain. Our international partners will aggressively market the benefits of SofPulse® to gain rapid acceptance in these territories,” Weisberg stated. The opportunities in these global markets is important to the growth of Endonovo. The International Society of Aesthetic Plastic Surgery (ISAPS) “International Survey on Aesthetics/Cosmetic Procedures Performed in 2020” reports the number one surgical procedure performed worldwide is “Breast Augmentation” which accounted for “1,624,281 procedures…Total surgical breast procedures performed worldwide was 3,062,897 out of the 10,129,528 surgical procedures performed in 2020.” The global breast reconstruction market witnessed a robust Compound Annual Growth Rate (CAGR) of 7.11%, valued at $2.68 billion in 2021, expected to appreciate and reach $4.98 billion by 2030, confirms Strategicmarketresearch.com. Alliedmarketresearch.com reported: “The global cosmetic surgery market is valued at $67.3 billion in 202...